Pilot study on light dosimetry variables for photodynamictherapy of barrett's esophagus with high-grade dysplasia

Kanwar R S Gill, Herbert C. Wolfsen, Norris W. Preyer, Marquitta V. Scott, Setha Gross, Michael B. Wallace, Linda R. Jones

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: Photodynamic therapy (PDT) is used to treat Barrett's esophagus with high-grade dysplasia and mucosal carcinoma. Outcomes are variable withsome patients having persistent disease, whereas others develop strictures. The aims of this study were (a)to compare porfimer sodium tissue uptake, light dose, and esophageal thickness with clinical outcomes and (b)to determine the selectivity of porfimer sodium uptake in diseased and normal epithelium. Experimental Design: Forty-eight hours after porfimer sodium infusion, patients underwent mucosal biopsy for quantification of the porfimer sodium. Laser light was delivered at 48 hours and again 24 or 48 hours later. Porfimer sodium was extracted from the biopsy samples and quantified using fluorescence spectroscopy. The enhanced photodynamic dose was determined as [porfimer sodium content*light dose/esophageal thickness]. PDT efficacy was determined 6 to 8 weeks later based on persistence or complete ablation of dysplasia or carcinoma. Results: Mean porfimer sodium content of 6.2 mg/kg (range, 2.6-11.2 mg/kg) and mean total light dose of 278 J/cm (range, 225-360 J/cm) resulted in a complete treatment. Mean porfimer sodium tissue content of 3.9 mg/kg (range, 2.1-8.1 mg/kg) and mean total light dose of 268 J/cm (range, 250-350 J/cm) resulted in an incomplete treatment. The total esophageal thickness (range, 1.7-6.0 mm) and enhanced photodynamic dose were correlated with treatment outcome. Conclusions: Esophageal thickness is the strongest predictor of treatment outcome. The porfimer sodium content of Barrett's and normal tissue is not significantly different. ''Photodynamic dose'' for esophageal PDTshould incorporate the esophageal thickness.

Original languageEnglish (US)
Pages (from-to)1830-1836
Number of pages7
JournalClinical Cancer Research
Volume15
Issue number5
DOIs
StatePublished - Mar 1 2009

Fingerprint

Dihematoporphyrin Ether
Barrett Esophagus
Light
Photochemotherapy
Carcinoma
Biopsy
Fluorescence Spectrometry
Pathologic Constriction
Lasers
Research Design
Epithelium

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gill, K. R. S., Wolfsen, H. C., Preyer, N. W., Scott, M. V., Gross, S., Wallace, M. B., & Jones, L. R. (2009). Pilot study on light dosimetry variables for photodynamictherapy of barrett's esophagus with high-grade dysplasia. Clinical Cancer Research, 15(5), 1830-1836. https://doi.org/10.1158/1078-0432.CCR-08-2317

Pilot study on light dosimetry variables for photodynamictherapy of barrett's esophagus with high-grade dysplasia. / Gill, Kanwar R S; Wolfsen, Herbert C.; Preyer, Norris W.; Scott, Marquitta V.; Gross, Setha; Wallace, Michael B.; Jones, Linda R.

In: Clinical Cancer Research, Vol. 15, No. 5, 01.03.2009, p. 1830-1836.

Research output: Contribution to journalArticle

Gill, KRS, Wolfsen, HC, Preyer, NW, Scott, MV, Gross, S, Wallace, MB & Jones, LR 2009, 'Pilot study on light dosimetry variables for photodynamictherapy of barrett's esophagus with high-grade dysplasia', Clinical Cancer Research, vol. 15, no. 5, pp. 1830-1836. https://doi.org/10.1158/1078-0432.CCR-08-2317
Gill, Kanwar R S ; Wolfsen, Herbert C. ; Preyer, Norris W. ; Scott, Marquitta V. ; Gross, Setha ; Wallace, Michael B. ; Jones, Linda R. / Pilot study on light dosimetry variables for photodynamictherapy of barrett's esophagus with high-grade dysplasia. In: Clinical Cancer Research. 2009 ; Vol. 15, No. 5. pp. 1830-1836.
@article{916ecdcf551d4d42aec29de791d9cc6e,
title = "Pilot study on light dosimetry variables for photodynamictherapy of barrett's esophagus with high-grade dysplasia",
abstract = "Purpose: Photodynamic therapy (PDT) is used to treat Barrett's esophagus with high-grade dysplasia and mucosal carcinoma. Outcomes are variable withsome patients having persistent disease, whereas others develop strictures. The aims of this study were (a)to compare porfimer sodium tissue uptake, light dose, and esophageal thickness with clinical outcomes and (b)to determine the selectivity of porfimer sodium uptake in diseased and normal epithelium. Experimental Design: Forty-eight hours after porfimer sodium infusion, patients underwent mucosal biopsy for quantification of the porfimer sodium. Laser light was delivered at 48 hours and again 24 or 48 hours later. Porfimer sodium was extracted from the biopsy samples and quantified using fluorescence spectroscopy. The enhanced photodynamic dose was determined as [porfimer sodium content*light dose/esophageal thickness]. PDT efficacy was determined 6 to 8 weeks later based on persistence or complete ablation of dysplasia or carcinoma. Results: Mean porfimer sodium content of 6.2 mg/kg (range, 2.6-11.2 mg/kg) and mean total light dose of 278 J/cm (range, 225-360 J/cm) resulted in a complete treatment. Mean porfimer sodium tissue content of 3.9 mg/kg (range, 2.1-8.1 mg/kg) and mean total light dose of 268 J/cm (range, 250-350 J/cm) resulted in an incomplete treatment. The total esophageal thickness (range, 1.7-6.0 mm) and enhanced photodynamic dose were correlated with treatment outcome. Conclusions: Esophageal thickness is the strongest predictor of treatment outcome. The porfimer sodium content of Barrett's and normal tissue is not significantly different. ''Photodynamic dose'' for esophageal PDTshould incorporate the esophageal thickness.",
author = "Gill, {Kanwar R S} and Wolfsen, {Herbert C.} and Preyer, {Norris W.} and Scott, {Marquitta V.} and Setha Gross and Wallace, {Michael B.} and Jones, {Linda R.}",
year = "2009",
month = "3",
day = "1",
doi = "10.1158/1078-0432.CCR-08-2317",
language = "English (US)",
volume = "15",
pages = "1830--1836",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Pilot study on light dosimetry variables for photodynamictherapy of barrett's esophagus with high-grade dysplasia

AU - Gill, Kanwar R S

AU - Wolfsen, Herbert C.

AU - Preyer, Norris W.

AU - Scott, Marquitta V.

AU - Gross, Setha

AU - Wallace, Michael B.

AU - Jones, Linda R.

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Purpose: Photodynamic therapy (PDT) is used to treat Barrett's esophagus with high-grade dysplasia and mucosal carcinoma. Outcomes are variable withsome patients having persistent disease, whereas others develop strictures. The aims of this study were (a)to compare porfimer sodium tissue uptake, light dose, and esophageal thickness with clinical outcomes and (b)to determine the selectivity of porfimer sodium uptake in diseased and normal epithelium. Experimental Design: Forty-eight hours after porfimer sodium infusion, patients underwent mucosal biopsy for quantification of the porfimer sodium. Laser light was delivered at 48 hours and again 24 or 48 hours later. Porfimer sodium was extracted from the biopsy samples and quantified using fluorescence spectroscopy. The enhanced photodynamic dose was determined as [porfimer sodium content*light dose/esophageal thickness]. PDT efficacy was determined 6 to 8 weeks later based on persistence or complete ablation of dysplasia or carcinoma. Results: Mean porfimer sodium content of 6.2 mg/kg (range, 2.6-11.2 mg/kg) and mean total light dose of 278 J/cm (range, 225-360 J/cm) resulted in a complete treatment. Mean porfimer sodium tissue content of 3.9 mg/kg (range, 2.1-8.1 mg/kg) and mean total light dose of 268 J/cm (range, 250-350 J/cm) resulted in an incomplete treatment. The total esophageal thickness (range, 1.7-6.0 mm) and enhanced photodynamic dose were correlated with treatment outcome. Conclusions: Esophageal thickness is the strongest predictor of treatment outcome. The porfimer sodium content of Barrett's and normal tissue is not significantly different. ''Photodynamic dose'' for esophageal PDTshould incorporate the esophageal thickness.

AB - Purpose: Photodynamic therapy (PDT) is used to treat Barrett's esophagus with high-grade dysplasia and mucosal carcinoma. Outcomes are variable withsome patients having persistent disease, whereas others develop strictures. The aims of this study were (a)to compare porfimer sodium tissue uptake, light dose, and esophageal thickness with clinical outcomes and (b)to determine the selectivity of porfimer sodium uptake in diseased and normal epithelium. Experimental Design: Forty-eight hours after porfimer sodium infusion, patients underwent mucosal biopsy for quantification of the porfimer sodium. Laser light was delivered at 48 hours and again 24 or 48 hours later. Porfimer sodium was extracted from the biopsy samples and quantified using fluorescence spectroscopy. The enhanced photodynamic dose was determined as [porfimer sodium content*light dose/esophageal thickness]. PDT efficacy was determined 6 to 8 weeks later based on persistence or complete ablation of dysplasia or carcinoma. Results: Mean porfimer sodium content of 6.2 mg/kg (range, 2.6-11.2 mg/kg) and mean total light dose of 278 J/cm (range, 225-360 J/cm) resulted in a complete treatment. Mean porfimer sodium tissue content of 3.9 mg/kg (range, 2.1-8.1 mg/kg) and mean total light dose of 268 J/cm (range, 250-350 J/cm) resulted in an incomplete treatment. The total esophageal thickness (range, 1.7-6.0 mm) and enhanced photodynamic dose were correlated with treatment outcome. Conclusions: Esophageal thickness is the strongest predictor of treatment outcome. The porfimer sodium content of Barrett's and normal tissue is not significantly different. ''Photodynamic dose'' for esophageal PDTshould incorporate the esophageal thickness.

UR - http://www.scopus.com/inward/record.url?scp=63549104439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63549104439&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-2317

DO - 10.1158/1078-0432.CCR-08-2317

M3 - Article

VL - 15

SP - 1830

EP - 1836

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -